Voclosporin (Lupkynis®). HTA ID: 23003

Assessment Status NCPE assessment ongoing
HTA ID 23003
Drug Voclosporin
Brand Lupkynis®
Indication Voclosporin is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).
Assessment Process
Rapid review commissioned 10/01/2023
Rapid review completed 10/02/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of voclosporin compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/03/2023
Pre-submission consultation with Applicant 23/05/2023
Full submission received from Applicant 20/09/2023
Preliminary review sent to Applicant 24/04/2024
NCPE assessment re-commenced 31/05/2024